Yungpo Bernard Su

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3K citations · Full text

Neoadjuvant Therapy, Chemotherapy Versus Cetuximab, Medicine +7

Concurrent Cetuximab, Cisplatin, and Concomitant Boost Radiotherapy for Locoregionally Advanced, Squamous Cell Head and Neck Cancer: A Pilot Phase II Study of a New Combined-Modality Paradigm

David G. Pfister, Yungpo Bernard Su, Dennis H. Kraus et al. · Journal of Clinical Oncology · 2006 · 298 citations

Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium

Manish A. Shah, Yelena Y. Janjigian, Ronald G. Stoller et al. · Journal of Clinical Oncology · 2015 · 176 citations

Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study

Neil D. Gross, David M. Miller, Nikhil I. Khushalani et al. · The Lancet Oncology · 2023 · 90 citations

Surgical Oncology, Survival Outcomes, Neoadjuvant Cemiplimab +9

Evaluation of Romidepsin for Clinical Activity and Radioactive Iodine Reuptake in Radioactive Iodine–Refractory Thyroid Carcinoma

Eric J. Sherman, Yungpo Bernard Su, Ashima Lyall et al. · Thyroid · 2012 · 67 citations · Full text